RxTrials Institute Drug Pipeline Alert
Nov. 14, 2007 | Vol. 5 No. 224
Ista Pharmaceuticals reported results from two Phase III trials of once-daily Xibrom, a new formulation of the company’s ocular nonsteroidal anti-inflammatory agent.
Lev Pharmaceuticals presented results from a Phase III trial of Cinryze in patients with acute attacks of hereditary angioedema (HAE), a genetic condition that causes recurrent and potentially life-threatening inflammation in the larynx, abdomen, face, extremities and urogenital tract.
Provectus Pharmaceuticals will begin Phase II testing of PH-10, a topical treatment for psoriasis.
Archemix has started a Phase IIa trial to evaluate the safety and efficacy of ARC1779 as an antithrombotic in patients suffering from acute coronary syndrome undergoing percutaneous coronary intervention.
Lundbeck has started Phase I trials to investigate the safety, tolerability and pharmacokinetic profile of Lu AA47070 in humans.
Allos Therapeutics has started patient enrollment in a nonrandomized, open-label, multicenter, dose-escalation Phase I study of the targeted chemotherapeutic agent RH1 in patients with advanced solid tumors or non-Hodgkin’s lymphoma (NHL).
The FDA has granted fast-track status to Dutch biotechnology company Crucell’s rabies monoclonal antibody cocktail.
Acambis has signed an exclusive agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis, for Acambis’ ChimeriVax-West Nile vaccine.
German drugmaker Direvo Biotech has signed an agreement with Pfizer to develop therapeutic proteases for different targets as potential treatments for various diseases.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.